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Background. Research on dairy foods to enhance weight and fat loss when incorporated into a modest weight loss diet has had
mixed results. Objective. A 15-week controlled feeding study to determine if dairy foods enhance central fat and weight loss when
incorporated in a modest energy restricted diet of overweight and obese adults. Design. A 3-week run-in to establish energy needs;
a 12-week 500kcal/d energy reduction with 71 low-dairy-consuming overweight and obese adults randomly assigned to diets: ≤1
serving dairy/d (low dairy, LD) or ≤4 servings dairy/d (adequate dairy, AD). All foods were weighed and provided by the met-
abolic kitchen. Weight, fat, intra-abdominal adipose tissue (IAAT), subcutaneous adipose tissue (SAT) macrophage number, SAT
inﬂammatory gene expression, and circulating cytokines were measured. Results. No diet diﬀerences were observed in weight, fat,
or IAAT loss; nor SAT mRNA expression of inﬂammation, circulating cytokines, fasting lipids, glucose, or insulin. There was a
signiﬁcantincrease(P = 0.02)inserum25-hydroxyvitamin DintheADgroup.Conclusion.Whether increaseddairyintakeduring
weight loss results in greater weight and fat loss for individuals with metabolic syndrome deserves investigation. Assessment of ap-
petite, hunger, and satiety with followup on weight regain should be considered.
1.Introduction
Obesity is a national epidemic with a multifaceted etiology
andequallycomplexsolutions.Epidemiologicalevidencehas
consistently shown the beneﬁts of increased dairy intake on
health, including an inverse relationship between dairy in-
take and body weight [1] and a lower incidence of insulin
resistance with increasing dairy intakes [2]. Zemel et al. [3]
ﬁrst showed the relationship between dairy foods and body
fat when conducting a clinical trial on the antihypertensive
eﬀectsofcalciuminobeseAfrican-Americans.Theirﬁndings
showed that increasing dietary calcium from approximately
400mg/d to ∼1,000mg/day, by the addition of yogurt to
the diet, for one year resulted in a 4.9kg reduction in
body fat. Further work has suggested that dietary calcium
with concomitant reductions in calcitriol could have anti-
inﬂammatory eﬀects at the level of the macrophage and
adipocyte.Thisbodyofworksuggeststhatcalcium-richdiets2 Journal of Obesity
produce signiﬁcant metabolic eﬀects that result in reduced
obesity risk and associated comorbidities.
Investigations that have examined the role of dairy prod-
uctsorcalciumonweightandfatlossinhumansubjectshave
providedmixedresults[4–7].Drapeauandcolleagues[4]ex-
amined changes in food patterns in the Qu´ ebec Family
Study, and reported increased consumption of fruits and
skimmed milk were 2 food groups that were negatively re-
lated to increases in body weight over time. Major et al.
[5] conducted a randomized, double-blinded placebo-con-
trolled study to compare the eﬀect of a 15-week weight loss
program using calcium plus vitamin D supplementation
versus placebo on fat loss. They found no statistically sig-
niﬁcant diﬀerence in fat loss for the calcium and vitamin-
D-supplemented group compared to the placebo group. But
when the data were examined for just the very low calcium
consumers (<600mg/d), a signiﬁcantly (P<0.01) greater
amount of weight and fat loss was observed in the Ca + D
group. However, there was also a corresponding reduction
in fat intake, so the investigators concluded that the fat loss
observed in the low calcium consumers was partially medi-
ated by the reduction in dietary fat intake. Zemel and col-
leagues [6] conducted a 12-week weight loss study in which
2 of the 3 groups were instructed to consume a diet either
low in dairy foods (≤1s e r v i n g / d )o ra d e q u a t ei nd a i r yf o o d s
(3 servings/d). The third group was given the low dairy diet
plus calcium supplementation equivalent to the ≥3d a i r y
foods/d group. All groups participated in a 500kcal energy
restriction weight loss period for 12 weeks. Zemel et al.
reported a signiﬁcantly greater weight and fat loss in the
adequate dairy group, an intermediate weight and fat loss
in the calcium-supplemented group, and the least weight
and fat loss in the low dairy group. Additional research by
Zemel et al. [7] in a weight loss model examined changes in
the distribution of body composition, based on DXA meas-
urements, with either adequate calcium or adequate dairy
intervention compared to low dairy diets and reported that
the low dairy diet resulted in 5.3% loss of abdominal fat
compared to losses of 12.9% and 14.0% for the adequate
calcium and adequate dairy diets, respectively.
Contrarytotheaboveﬁndings,Holeckietal.[8]reported
nosigniﬁcantdiﬀerencesinchangesinbodyweight,bodyfat,
parathyroid hormone, or 25-OH vitamin D concentrations
in 40 obese women who had been divided into 2 groups: diet
with Ca + D supplements versus diet only. Likewise Harvey-
Berino et al. [9] reported no signiﬁcant diﬀerence between
groups in weight or body fat losses after 12 months of a
500kcal/d reduction in energy with either 1 serving of dairy
foods/d or 3-4 servings of dairy foods/d incorporated into
the diet plan. Thompson et al. [10] reported results from
a randomized trial with three −500kcal/d restricted diets
(control, low calcium, and high calcium) and found no
signiﬁcant diﬀerences in weight and fat loss between diet
groups.
Several mechanisms of action have been proposed to
explain the potential eﬀects of high-calcium diets to reduce
adiposity and inﬂammation. Higher intake of calcium may
decrease the absorption of fat when calcium-fatty-acid soaps
are formed, resulting in increased fecal fat excretion [11]. In
addition, increased Ca intake can promote lipid oxidation
[12] and/or blunt parathyroid hormone release [13]. Addi-
tionally, observations have been made that suggest that the
modulation of adipocyte intracellular calcium [Ca2+
i]b y
the calcium-regulated hormone calcitriol may be important
in regulating adipocyte function, with reductions in cal-
citriol following dietary calcium provision promoting lipid
mobilization while reducing energy storage through changes
in metabolic gene expression [3]. Notably, the work of
J o n e se ta l .[ 14] demonstrated an increase in [Ca2+
i]-pro-
moted energy storage pathways in human adipocytes by
stimulating expression and activity of fatty acid synthase and
by inhibiting lipolysis.
Chronic inﬂammation of white adipose tissue (WAT),
especially in visceral depots, contributes to the pathogen-
esis of obesity-related morbidities including insulin resis-
tance and type 2 diabetes [14–16]. Macrophages inﬁltrate
WAT with increasing adiposity and are a prominent cellular
source of proinﬂammatory cytokine production [14].Recent
cell culture data from Sun and Zemel [15] indicated that cal-
citriol increased proinﬂammatory cytokine gene expression
and protein secretion from adipocytes and macrophages,
a n dt h i sr e s p o n s ew a sd e p e n d e n to nC a 2+
i-provoked reactive
oxygen species (ROS) generation. Coculture of both cell
types increased gene expression and protein secretion of
proinﬂammatory cytokines, which was further enhanced
by calcitriol [15]. In vivo evidence for the potential anti-
inﬂammatory properties of high dietary calcium both with
andwithoutdairywasdemonstratedintheaP2-agoutitrans-
genic mouse model of obesity, in which a high Ca, nonfat
drymilkprotein-baseddietreducedWATinﬂammatorygene
expression and circulating cytokines. Furthermore, weight
loss has been shown to promote a reduction in plasma mark-
ers of inﬂammatory cytokines [16] and lower inﬂammatory
marker gene expression in subcutaneous WAT, at least with
very low-calorie diets.
Obesity is a multifaceted disease and diﬃcult to study
outside of a controlled environment. Previous results assess-
ing the roles of dairy and calcium on weight loss have been
reported from studies in which controlled conditions were
not optimal since they were typically performed in a setting
that required subjects to prepare their own food, which
might have contributed to the variability in results. There-
fore, we proposed to examine the impact of dairy on adipos-
ity and metabolism under conditions of a controlled feed-
ing study. We examined, under the “gold standard” of a
controlled feeding trial, the eﬀects of 3-4 servings/d of
dairy foods during moderate energy restriction on central
fat and weight loss, changes in intra-abdominal adipose
tissue (IAAT), metabolic rate, substrate utilization, vitamin
D status, adipocyte size and subcutaneous adipose tissue
(SAT) inﬂammation markers, and inﬂammatory cytokines.
Our primary hypotheses were as follows: the inclusion of
adequate servings of dairy foods (3-4/d) in a modest energy-
restricted diet would (1) signiﬁcantly increase weight and
body fat loss compared to a control diet, (2) result in greater
fat loss from IAAT depots, (3) decrease adipocyte size and
inﬂammationbyreducingWATmacrophageinﬁltration,and
(4) reduce systematic inﬂammatory markers.Journal of Obesity 3
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Figure 1: Study design.
2.SubjectsandMethods
2.1. Study Design. Healthy women, aged 20–45 years, and
healthy men, aged 20–50 years, were enrolled in a 15-week
controlled feeding study in which all foods were provided or
prepared by the Metabolic Food Laboratory (MFL) at the
USDA, ARS, Western Human Nutrition Research Center
(WHNRC). The 15-week study was divided into a 3-week
“run-in” period, during which subjects were weighed daily
and caloric intake adjusted to maintain body weight, thereby
establishing energy requirements. The “run-in” period was
followedbya12-weekenergyreductionperiod(−500kcal/d)
(Figure 1). Energy intake for weight maintenance was ini-
tially calculated based on the DRI equation for overweight
and obese adults [17]. Body weight was measured and
recorded daily using an electronic scale. After a 5 day diet
adjustment period, if weight increased or decreased for 3
consecutive days, caloric intake was adjusted (either up or
down) until daily weight measurements were stable. During
the last ﬁve days of the run-in period, subjects were assumed
to be in energy balance, and this energy intake level was
used to determine the reduced energy intake for the 12-week
intervention period.
2.2. Subject Screening and Selection. Overweight and obese
adultfemalesandmaleswererecruitedfromthefaculty,staﬀ,
and student populations at UC-Davis as well as the greater
Davis and Sacramento communities. The lower cap on the
age limit for women was used to avoid hormonal changes
associated with the perimenopausal period that might aﬀect
endocrine parameters and related study outcomes. Body
mass index was between 28 and 37kg/m2.B a s e do nad a i r y
and calcium screening questionnaire, all participants were
habitually low dairy consumers, deﬁned as ≤1 serving of
dairy/d and a total calcium intake ≤600mg/d from all
sources including dairy. All were weight stable, deﬁned as no
more than 3kg weight loss during three months preceding
the intervention. Exclusion wasbasedonnot meeting the age
anddairyservingcriteria,diagnosisoftype2diabetesrequir-
ing the use of any oral antidiabetic agent and/or insulin,
fasting glucose ≥1 1 0m g / d L ,a d v e r s er e s p o n s et os t u d yf o o d s
(lactose intolerance, dairy intolerance, dairy allergy deter-
mined by self-report), history or presence of signiﬁcant met-
abolicdisease(i.e.,endocrine,hepatic,orrenal),useofblood
pressure- or lipid-altering medications, resting blood pres-
sure ≥160/100mg/Hg, total cholesterol ≥300mg/dL, triglyc-
eride value ≥400mg/dL, or LDL ≥160mg/dL, history of
eating disorder, presence of active gastrointestinal disorders
such as malabsorption syndromes, pregnancy or lactation,
use of obesity pharmacotherapeutic agents within the last 12
weeks, use of over-the-counter antiobesity agents (e.g., those
containing phenylpropanolamine, ephedrine, and/or caf-
feine) within the last 12 weeks, use of calcium supplements
in the past 12 weeks, recent (past four weeks) initiation
of an exercise program, recent (past 12 weeks) initiation of
hormonal birth control or change in hormonal birth control
regimen, use of tobacco products, and exercise more than 30
minutes/day.
2.3. Subject Randomization and Treatment. Body composi-
tion was assessed during the “run-in” period, and because
body fatness could potentially aﬀect the outcome, sub-
jects were pair-matched based on percent body fat (%BF)
(to ensure an equal degree of body fatness in each treatment
arm prior to the intervention) and randomly assigned to
one of two treatment groups: low dairy (LD) (≤1 serving/d)
or adequate dairy (AD) (3-4 servings/d). Enrollment was
continuous with a new cohort starting approximately every
8 weeks. Consequently, volunteers were enrolled year-round.
Since this strategy could inﬂuence a subject’s vitamin D
status, the season at time of enrollment was coded in the
database for use in the statistical analysis. The consort
diagram (Figure 2) provides information on the number of
eligible participants versus enrolled participants. Forty per-
cent of the participants were nonwhite, and 25% of those
were of Hispanic origin.
2.4. Food Intake. The diets for the treatment arms were con-
structed to provide comparable levels of macronutrients and
ﬁber and to approximate the average composition of caloric
consumption in the US (fat ∼35% of total energy, carbo-
hydrates ∼49%, protein ∼16%, and ﬁber 8–10g/1000kcal).4 Journal of Obesity
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Figure 2: Consort diagram. Six individuals withdrew from the study prior to protocol completion and were excluded from data analysis.
Nutritional supplements were not permitted, and caﬀeine
intake was maintained at a constant level (individualized for
each patient, based on baseline assessment). All foods were
provided by the MFL of the WHNRC for the duration of
the study. Diets were prescribed and monitored as follows:
during the 3-week “run-in” phase, subjects were fed at the
WHNRC dining room and during that time they were fa-
miliarized with the diet and instructed on serving sizes and
how to note discrepancies in study diaries; subjects were
required to eat 2 of the 3 meals/d in the dining room. The
third meal was packed to go. Typically, subjects reported to
the WHNRC dining room for breakfast, lunch was packed
to go, subjects returned to the WHNRC for dinner, and the
evening snack was packed to go. All weekend meals were
packed to go. The pattern of eating 2 of the 3 meals/d at the
WHNRC was continued during the ﬁrst two weeks of the
energy restriction intervention. Thus, for the ﬁrst 5 weeks of
the study, most meals were consumed at the WHNRC. For
weeks 3–9 of intervention, subjects were “free-living,” but all
food was weighed, measured, and provided by the MFL staff
for each individual’s speciﬁc caloric needs. During this free-
living period, to ensure freshness and maintain food safety
standards,freshproduceandallpreparedfoodswere“packed
out”twiceweekly(TuesdayandFriday)foreachsubject.Sub-
jects were instructed by MFL staﬀ on proper preparation for
a l lf o o d sc o n s u m e da th o m e .A l ls u b j e c t sw e r ep r o v i d e dw i t h
preprinted food records corresponding to the foods to be
consumed on each day during the “pack-out” period. Food
records were reviewed when subjects returned to pick up
the next food allotment. For the last 3 weeks of intervention
(weeks 10–12), subjects returned to the WHNRC and once
again ate 2 of 3 meals/d in the dining room. Based on a
2100kcal menu, the adequate dairy (AD) diet included 3-4
servings of milk, yogurt, and cheese per day and averaged
1339mgCa/d from all sources. The low dairy (LD) diet had
≤1 serving of dairy (e.g., milk, yogurt, or cheese) per day
with an average calcium intake of 460mg/d from all sources.
Subjects in the AD group utilized dairy products ranging
fromlow-orreduced-fattofull-fatproducts;speciﬁcally1or
2% fat milk depending on caloric needs, low-fat yogurt, and
full-fat cheese. Independent laboratory analysis (Covance
Inc., Madison, Wis) of composites made from the 7 day
menu at 1800kcal (the most often prescribed level during
intervention) were done to conﬁrm calcium content of the
diet.
2.5. Compliance. Daily diet records were the basis for deter-
mining compliance. Preprinted diet records showing all
menu items and amounts were given to each subject at each
meal. In addition to the direct observation by the MFL staﬀ
during in-house eating, subjects checked (
√
) each food item
indicating it was eaten and recorded any deviations when
they occurred. The diet record was returned to the study di-
etitian uponcompletionofthemealduringthein-houseeat-
ing phase and biweekly during the “pack-out” phase. Diet
diaries during the initial feeding weeks allowed for the train-
ing of subjects on correct procedures for diet diaries. Records
were evaluated and ap ri o ridetermination of compliance was
based on adherence to (1) diet treatment: either LD (≤1
serving/d) or AD (3-4 servings/d), (2) energy intake within
200kcal of energy prescription, and (3) for the AD group
95% consumption of the 294 total dairy servings during the
12week intervention. Only subjects who met all compliance
criteria for a given week were recorded as compliant for that
week. Total study compliance was deﬁned as meeting weekly
compliance for 10 of the 12 weeks. Dairy food servings con-
sisted of 8oz. (240mL) low-fat (1%) or reduced-fat (2%)
ﬂuid milk, 8oz. (240mL) low-fat yogurt, 2oz. (56g) pro-
cessed cheese or 1.5oz. (42g) natural cheese delivering 250–
350mgCa, and at least 6 grams of dairy protein per serving.
During the course of the project, individual circumstances
arose in which subjects were not able to attend meals at the
WHNRC dining room. In these cases, food and meals were
packed and sent home with instructions on preparation
and completion of the diet record according to the studyJournal of Obesity 5
Table 1: Average nutrient distribution over a 7-day menu for ade-
quate and low-dairy diets at 1800 kilocalorie intake.
Adequate dairy Low dairy
Nutrient Mean ± SD Mean ± SD
Energy, kcal 1800.3 ± 6.1 1813.9 ± 52.6
Total fat, g (% energy) 71.5 (35.7) ± 1.3 73.1 (36.3) ± 2.8
Carbohydrate, g
(% energy) 223.0 (49.5) ± 4.9 223.7 (49.3) ± 7.1
Protein, g (% energy) 74.9 (16.6) ± 2.7 73.9 (16.3) ± 4.7
Animal protein, g 50.5 (11.2) ± 6.8 46.2 (10.2) ± 6.1
Vegetable protein, g
(% energy) 24.5 (5.4) ± 5.4 27.7 (6.1) ± 5.6
Cholesterol, mg 211.8 ± 111.6 217.0 ± 118.9
Saturated fat, g 22.6 ± 4.8 18.2 ± 5.9
Monounsaturated, g 26.8 ± 4.6 29.7 ± 4.2
Polyunsaturated, g 17.0 ± 3.8 19.4 ± 3.7
Vitamin D (calciferol) μg8 . 0 ± 2.6 3.2 ± 3.5∗
Calcium, mg 1288.4 ± 94.6 434.6 ± 56.6∗
Values are mean + SD for a 7-day menu.
∗Denotes signiﬁcant diﬀerence, P<0.001.
guidelines. Instances of illness, family emergencies, and so
forth, in which diet treatment was not maintained, were ac-
counted for in the overall compliance established for the
study (i.e., 10 out of 12 weeks). All the 71 subjects that
completed the study met compliance criteria. Macronutrient
intake for both the AD and LD diets are shown in Table 1.
2.6. Body Composition Measurements. Weight was measured
on an electronic scale (Scale-tronic model 6002; Wheaton,
Ill, USA) to the nearest 0.1kg with subjects in light clothing,
all jewelry removed, pockets emptied, and shoes removed.
Height was measured using a wall-mounted stadiometer
(Ayrton Stadiometer model S100; Prior Lake, Minn, USA).
Subjects were instructed to stand erect with the head level
and to inhale fully. Height was measured and recorded to
the nearest 0.1cm. Body mass index was calculated as kg/m2.
Waist circumference was measured in the standing position
against bare skin with the abdomen relaxed and the arms
hanging at the sides. The smallest horizontal circumference
midway between the lateral lower rib and the iliac crest
and at the end of a normal exhalation was recorded to the
nearest 0.1cm. The average of two readings was reported
for weight, height, and waist circumference. Weight was
measured weekly during the intervention phase of the study.
Total lean and fat masses and percent body fat were as-
sessed using dual energy X-ray absorptiometry (DXA, GE
Lunar, Prodigy Model) during the run-in period and at the
end of the 12-week intervention. Daily calibration proce-
dures were carried out per manufacturer instructions. To
reduce the variance in the measurement data, all DXA scans
were analyzed by a single operator.
2.7. Intra-Abdominal Adipose Tissue Measurements (IAAT).
IAAT was measured using computed tomography (CT)
transabdominal slices (Siemens Somaton 16 CT Scanner).
Measurements were made at the level of the L4-L5 inter-
vertebral space following procedures developed by Clasey
etal.[18].Scansliceswere0.5cmwiththesubjectinasupine
position and arms stretched above the head. Measurements
were made with no angulation and using a lateral pilot
scout scan to determine proper location. Adipose tissue area
was assessed using an attenuation range from −190 to −30
Hounsﬁeld units. IAAT includes the adipose tissue contained
in a measurement boundary formed by the internal most
aspect of the abdominal and oblique muscle walls and the
posterior aspect of the vertebral body. IAAT measurements
by CT were made during the run-in and at the end of the 12-
week intervention. All measurements were made following a
12-hr overnight fast.
2.8. Resting and Postprandial Metabolic Rate (RMR and
PPMR). Subjects reported to the WHNRC metabolic unit
for the measurement of metabolic rate in the morning fol-
lowing a 12-hr overnight fast. Subjects were made comfort-
able in a hospital bed and were instructed to rest quietly in
a reclined position for 15 minutes. An automated metabolic
measuring cart (Truemax 2400 Metabolic Measurement Sys-
tem, Parvomedics, Salt Lake City, Utah, USA) was used to
measure rates of O2 consumption (VO2) and CO2 produc-
tion (VCO2). Gas analyzers were calibrated using a certiﬁed
gas mixture of known O2 and CO2 concentrations, and the
ﬂowmeter was calibrated using a 3L syringe. The metabolic
cart was calibrated prior to the RMR measurement and
recalibrated with a new tube and ﬁlter prior to the controlled
lunch.Respiratorygaseswerecollectedwhilesubjectswerein
a semireclined position and wore a facemask ﬁtted securely
covering the nose and mouth. The facemask was attached
to tubing connected to the cart mixing chamber. Through
the facemask, subjects inhaled room air, and all expired
breath was trapped by the mask and directed to the cart
mixing chamber for volume and gas analyses. For RMR, re-
spiratory gas exchange measurements were made for 20–30
minutes. The minute by minute data for this session were
evaluated using a mathematical algorithm to determine the
subject steady-state RMR. Respiratory exchange ratio (RER),
VCO2/VO2, was also determined from the steady-state RMR
measurement. For postprandial metabolic rate (PPMR), res-
piratory gases were collected for 10 minutes every hour over
10hrs. following the meal, minute by minute data for these
sessions were also run through the mathematical algorithm
to determine the subject steady state PPMR and the post-
prandial RER for that hour. Throughout the protocol, sub-
jects remained in their hospital beds. They consumed a
controlled breakfast served between 08:25–08:45, and a con-
trolled lunch served between 12:35–13:00, representing 25%
and 30% of their daily intervention energy prescription,
respectively. Data collection ended at 18:00, four hours after
the lunch meal. This protocol was scheduled during the last
week of the run-in period and the ﬁnal week of intervention.
Energy expenditure was calculated using the Weir equation
[19] and converted to kcal/day:
kcal/min = (3.941 ×VO2)+(1.106 ×VCO2)
−

2.17 × urinary N

.
(1)6 Journal of Obesity
Units for VO2 and VCO2 are in L/min. To estimate urinary
nitrogen excretion, in g/min, a spot urine collection was
made at the time of the RMR measurement, and a constant
rate of protein catabolism was assumed, equivalentto the 24-
hr protein intake, as reported by Bingham [20].
2.9. Assessment of Physical Activity. Subjects were instructed
to maintain their usual physical activity throughout the
study. Physical activity was monitored using an Acti-
cal physical-activity-monitoring device (Philips Electronics,
Bend, Ore, USA). The Actical is an omnidirectional acceler-
ometer that provides an objective and quantiﬁable measure
of physical activity. Digital integration data acquisition
incorporates intensity of movement into the activity count
for sedentary, light, moderate, and vigorous levels of activity.
SubjectswereinstructedtoweartheActicalduringallwaking
hours, except for bathing or other activities that involved
submersion in water, for the week (7 days). The Actical was
attached to a belt and worn over the left hip. At the end
of the week, subjects returned the Actical to the WHNRC
Physiology Support Lab where the data were downloaded
for conﬁrmation of completeness in terms of the number of
days of data collection, frequency, and intensity of activity
sessions. A day was considered complete if the Actical con-
tained at least 12 hours of data. If there were fewer than 5
weekdays and 2 weekend days of recorded data, the Actical
was returned to the subject for additional days. Actical data
were collected during the run-in and at weeks 4, 8, and 12 of
intervention.
2.10. Subcutaneous Adipose Tissue (SAT) Biopsies. Subcuta-
neous adipose tissue biopsies were obtained at the UC Davis
Medical Center Clinical and Translation Science Center at
run-in and at the end of the 12-week intervention following
a 12-hr overnight fast. The study physician or nurse prac-
titioner sterilized the gluteal region with a betadine scrub
followed by wiping with alcohol. A 2% lidocaine HCL so-
lution was used to desensitize the area by injecting approx-
imately 4–8mL of lidocaine in a fan-shaped area of the
gluteus. A 14-gauge, 1.5 inch needle was used on a 20mL
syringeandinsertedatthesiteoflidocaine HClinjection. Fat
wasaspiratedassuctionwasappliedtothesyringeandneedle
and repeatedly rotated until approximately 4–6mL adipose
tissue was obtained. Following biopsy, the area was treated
again with Betadine and bandaged. Biopsies at run-in and at
week 12 were collected from opposite side of the buttocks.
Each sample was immediately rinsed in ice cold phosphate
buﬀered saline (PBS) to remove blood and further processed
in 1 of 2 ways: (1) rinsed in RNAlater solution (Ambion,
Austin, TX) and placed in ∼25mL RNAlater solution or (2)
again rinsed in fresh ice cold PBS and 3 aliquots frozen
in liquid nitrogen for later histological analyses. RNAlater
treated samples were placed on ice for transport to the
WHNRC where samples were gently rocked overnight in a
4◦C refrigerator, stripped of RNAlater solution and stored at
−80◦C until isolation of total RNA.
2.11. Total RNA Isolation and Gene Expression Analysis. Total
RNAwasisolatedfromSATusingtheRibopureKit(Ambion,
Austin, TX) according to manufacturer’s instructions. RNA
abundancewasquantiﬁedusingaNanoDropND-1000Spec-
trophotometer (NanoDrop Technologies, Wilmington, DE).
cDNA was synthesized from total RNA for each sample using
Superscript III First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA) according to manufacturer’s in-
structions. Gene expression measured by quantitative real
time PCR utilized gene-speciﬁc TaqMan primers and FAM-
MGB labeled probes (Assays-on-Demand, Applied Biosys-
tems, Foster City, CA) analyzed in duplicate for each sample
using an ABI 7900HT instrument. The ampliﬁcation cross-
ing threshold (Ct) for the endogenous control gene (hprt1;
hypoxanthine guanine phosphoribosyl transferase 1) was
determined for each sample to correct for template loading
diﬀerences across all target genes (ΔCt = target gene Ct −
control gene Ct). The expression values (baseline and end-
point) were determined relative to average baseline expres-
sion (not individual subject baseline pre-intervention). Due
to the high inter-subject variability, only samples for which a
baseline and endpoint expression value was determined were
used in the analysis (Low Dairy = 29 and Adequate Dairy =
26).
2.12. SAT Macrophage Inﬁltration and Inﬂammatory Pheno-
type. Thawed samples were ﬁxed in 10% neutral buﬀered
formalin overnight prior to immunological analysis of ma-
crophage number and adipocyte size in the Spurlock labora-
tory at Iowa State University. Brieﬂy, samples were removed
from ﬁxative no later than 24hr after collection and embed-
d e di np a r a ﬃn. Paraﬃn-embedded samples were sectioned
to 4μm thickness and mounted onto microscope slides.
Slides were subjected to hematoxylin and eosin Y staining on
an automatic stainer. Cover slips were applied with mount-
ing medium and slidesplaced in a 5◦C oven to dry overnight.
Visualization of adipocyte number and size on the hema-
toxylinandeosinY(H&E)stainedslideswasperformedwith
a Zeiss light microscope and processed with AxioVision
4.8 software. Counting and measurement of adipocytes was
carried out at 20x magniﬁcation on a randomly selected ﬁeld
by a single investigator blinded to sample treatment group.
The ﬁeld of vision was subdivided into four randomly placed
71,765.96μm2 boxes, and all adipocytes that were in or par-
tially within a box were counted. Only adipocytes completely
inside the designated boxes were measured for area. The cell
number and areas from the four designated counting areas
were combined for an average value. Following microscopy,
the cover slips were removed and samples deparaﬃnized and
rehydrated by submersion in xylene for 5 minutes repeated
twice,100%EtOHtwicefor3minuteseach,90%EtOHtwice
for 3 minutes each, 70% EtOH twice for 3 minutes each,
H2O for 3 minutes each, and tris-buﬀered saline (TBS)
for 5 minutes each. Following rehydration, samples were
proteolytically digested with 2% proteinase K in TBS for
10 minutes and placed in TBS for 5 minutes. Slides were
removed from TBS and treated with peroxisidase block
(Dako, Glostrup, Denmark) for 5 minutes and rinsed with
distilled water before being placed in fresh TBS for 5 min-
utes. Samples were treated with primary antibody (mouse
antihuman CD68, a panmacrophage marker) for 30 minutesJournal of Obesity 7
atroomtemperatureandplacedbackintoTBSfor5minutes.
Samples were incubated with secondary antibody (HRP
rabbit antimouse IgG) for 30 minutes at room temperature
and placed back into TBS for 5 minutes. DAB chromogen
substrate (Dako, Glostrup, Denmark) was applied to slides
for 15 minutes to obtain the appropriate stain darkness,
and slides were then dipped into distilled water prior to
counterstaining. Slides were counterstained in one quarter
strength Harris hematoxylin for 1min, rinsed with double-
distilled H2O, dipped brieﬂy in diﬀerentiating solution
(Sigma-Aldrich, St. Louis, Mo, USA) two times, rinsed
with tap water, and placed in Scott’s tap water substitute
for 1 minute, 95% EtOH for 30 seconds, then eosin Y
solution for 1 minute. Following counterstaining, samples
were dehydrated 1 minute in 95% EtOH repeated twice, 2
minutesin100%EtOHrepeatedtwice,thenclearedinxylene
for 2 minutes. Dehydrated samples were allowed to dry
beforeremountingthecoverslip.Arandomlyselectedareaof
the sample was visualized with a Zeiss light microscope and
processed as previously described except only the adipocyte
number, and the total number of CD68-positive (brown-
stained)cellswerecounted.Tocalculatethe%CD68-positive
macrophage cells, the number of adipocytes counted in the
same ﬁeld of vision as the CD68 cells were added to the
positive cells to get the total number of cells, and the number
of CD68-positive cells was divided by the total cell count.
2.13. Systemic Inﬂammatory and Adipokine Markers. Fasting
levels of insulin, leptin, adiponectin, proinﬂammatory cy-
tokines (IL-1β,I L - 6 ,I L - 8 ,T N F α, PAI-1) and the acute
phase C-reactive protein (CRP) were measured at the run-in
period and at 12-week of intervention. Serum levels of high-
sensitivity CRP (hsCRP) were measured using a chemilumi-
nescence analyzer and high-sensitivity CRP kit (Immulite,
Siemens Diagnostics; Deerﬁeld, Ill, USA). All other inﬂam-
matory markers were measured using multiplex technology
using manufacturer’s instructions (Millipore Corporation,
Billerica, MA and BioPlex, Bio-Rad, Richmond, Va, USA).
2.14. Blood Samples. Sterile phlebotomy procedures were
followed to draw two 5mL serum separator tubes (SST) and
one 3mL EDTA tube of blood during subject screening.
These samples were sent to the CLIA-certiﬁed clinical
chemistry laboratory at the UC Davis Medical Center for
routine analysis of complete clinical chemistry panel, lipid,
liver, and thyroid assessment and complete blood count
with diﬀerentials. Results were reviewed to ensure that
values were within normal clinical ranges. Fasting blood was
alsodrawnatrun-inandweek-12ofintervention,andserum
and plasma were stored at −80◦C until analyzed. Samples
for glucose, lipids, and triglyceride analyses were sent to the
UC Davis Medical Center for analysis.
Serum vitamin D (calciferol) metabolites (25-OH vita-
min D and 1,25(OH)2D) were analyzed using standard
RIA procedures (DiaSorin, Stillwater, MN and Immunodi-
agnostics Systems [IDS], Fountain Hills, Az, USA). Samples
were processed in accordance with manufacturer’s instruc-
tions. 25-hydroxyvitamin D was assayed using an equilib-
riumRIAprocedurebasedonanantibodywithspeciﬁcityfor
25(OH)D. The sample, antibody, and tracer were incubated
for 90 minutes at 20–25◦C. Phase separation was accom-
plished after 20 minute incubation at 20–25◦C with a second
antibody-precipitating complex. An NSB/addition buﬀer
was added after this incubation prior to centrifugation to aid
in reducing the nonspeciﬁc binding. 1,25-dihydroxyvitamin
D was analyzed using an immunodiagnostics system (IDS)
RIA assay that is a complete assay system for the puriﬁcation
of1,25(OH)2Dinsamplesbyimmunoextractionfollowedby
quantitation by 125IR I A .
Intact parathyroid hormone was analyzed using an Im-
mulite instrument and a solid phase two-site chemilumines-
cent enzyme-labeled immunometric assay (Siemens Diag-
nostics; Deerﬁeld, Ill, USA).
3. StatisticalPower,Sample Size,
andAnalysis
Samplesizewasdeterminedbypowercalculationsusingdata
from a multicenter study that employed a dairy intervention
during weight loss [6]. Power calculations for weight loss
were based on treatment diﬀerences of 4.57kg. Fat loss cal-
c u l a t i o n sw e r eb a s e do nat r e a t m e n td i ﬀerence of 2.47kg.
Based on a standard deviation of 6.32kg and an alpha level
of 0.05, a sample size of 35 per treatment group provided
a power of 84.6%. For fat loss, a sample size of 35 with a
standard deviation of 2.65kg and an alpha of 0.05 resulted in
a power calculation of 97%.
Data analysis included descriptive statistics for physical
and clinical characteristics and various study-related hor-
mones. Data were evaluated for normality and transformed
as needed prior to statistical analysis. Associations among
variables were evaluated using Pearson’s correlations, and
signiﬁcant eﬀects of time and treatment were determined by
analysis of variance (ANOVA). All statistical analyses were
performed using SAS version 9.2 (SAS Institute, Cary, NC,
USA).
4. Results
Physical characteristics of the subjects at run-in are shown in
Table 2. Body weight, fat, and BMI were within the bounds
of overweight and obesity classiﬁcations. Fasting plasma or
serum concentrations of glucose, triglycerides, and lipids
a sw e l la sb l o o dp r e s s u r e sw e r en o r m a l .T h ea v e r a g ev a l u e
for serum 25(OH)D was below the recommended levels,
50nmol/L, at the run-in period and ranged from 10–
80nmol/L, consistent with the expectation that subjects were
recruited as low-dairy consumers. Values for PTH were
within normal limits.
Results for the primary outcomes, for example, changes
in body weight, body fat, and intra-abdominal adipose
tissue are displayed in Table 3. Analysis of variance indicated
a signiﬁcant time eﬀect but no treatment eﬀect. In other
words, both groups lost signiﬁcant amounts of body weight,
body fat, and intra-abdominal adipose tissue over time, but
inclusionofdairyproductsintotheenergy-restricteddietdid
not result in greater weight, fat, or IAAT losses for the AD
group. There was no signiﬁcant loss in lean body mass in8 Journal of Obesity
Table 2: Physical characteristics of subjects at run-in.
Parameter (N = 71) Mean ± SD Minimum Maximum
Age, yrs 32.5 ± 9.5 19 50
Height, cm 167.9 ± 8.7 150.0 188.6
Weight, kg 91.1 ± 11.1 62.1 113.4
Body fat, kg 38.8 ± 7.1 18.9 54.0
Body fat, % 43.1 ± 6.9 22.4 55.1
Lean body mass, kg 48.4 ± 9.5 34.0 71.5
IAAT, cc 92.4 ± 23.5 55.8 177.6
Waist
circumference, cm 94.4 ± 8.1 76.0 114.6
Total cholesterol,
mg/dL 159.4 ± 27.6 99.0 221.0
HDL, mg/dL 36.7 ± 11.5 19.0 71.0
LDL, mg/dL 104.7 ± 21.6 53.0 145.0
Triglycerides, mg/dL 89.4 ± 40.5 33.0 196.0
Glucose, mg/dL 83.0 ± 8.6 68.0 107.0
SBP, mmHg 111.2 ± 9.2 92.0 136.0
DBP, mmHg 66.5 ± 8.5 51.0 98.0
PTH, pg/mol 45.7 ± 18.1 18.8 97.4
25(OH)D, nmol/L 35.1 ± 15.1 10.1 80.4
Values are mean + SD. IAAT: intra-abdominal adipose tissue; HDL: high-
density lipoprotein; LDL: low-density lipoprotein; SBP: systolic blood
pressure; DBP: diastolic blood pressure; PTH: parathyroid hormone.
Table 3: Change in weight, body fat, and intra-abdominal adipose
tissueinadultwomenandmenconsuminglow-dairy(LD)oradeq-
uate dairy (AD) diets after a 12-week caloric restriction interven-
tion.
Treatment Δ Weight, kg Δ Body fat, kg Δ IAAT, cc
AD −6.3 ± 2.9∗∗ −5.2 ± 2.8∗∗ −8.5 ± 6.6∗∗
LD −6.0 ± 3.1∗∗ −5.1 ± 3.0∗∗ −8.9 ± 8.5∗∗
Values are mean ± SD. IAAT: intra-abdominal adipose tissue.
∗∗P = 0.01. Signiﬁcant time eﬀect only, no signiﬁcant diﬀerences were
observed by treatment group.
either group during the intervention (LD = −0.6kg; AD =
−0.83kg).
Although there was no signiﬁcant treatment eﬀect on
body fat loss, changes at a cellular level may be observed
before whole body changes can be seen; therefore, we exam-
ined adipocytes to determine if there was a treatment eﬀect
on adipocyte size and adipose tissue macrophage quantity.
There was a trend (P = 0.065) toward smaller adipocyte size
in the AD group with weight loss (LD −238.6 ± 375806;
AD −1562.8 ± 2558.8μM2). The change in macrophage
number relative to the total number of adipocytes did not
change during the study. Changes in the relative transcript
abundances for inﬂammatory (TNF-α, IL-6, MCP-1) and
metabolic (FAS and UCP2) genes in SAT were not diﬀerent
between treatment groups, and there were no time x treat-
ment interactions; thus, all samples (LD and AD; n = 55)
were combined to determine if there was an eﬀect of weight
loss(time)(Table 4).Mosttranscriptlevelswerenotchanged
Table 4: Relative transcript abundances of inﬂammatory and
metabolic markers in subcutaneous adipose tissue before and after
diet intervention for all subjects.
Gene Baseline Endpoint
TNF-α 100.0 ± 8.3 97.1 ± 7.3
IL-6 100.0 ± 11.1 150.9 ± 23.1∗
MCP-1 100.0 ± 10.5 105.2 ± 8.5
CD68 100.0 ± 5.3 116.5 ± 8.2
CD11b 100.0 ± 10.0 117.3 ± 12.0
CD11c 100.0 ± 9.1 105.4 ± 8.5
CD11d 100.0 ± 6.2 133.2 ± 9.6∗∗
IL-1β 100.0 ± 14.1 114.8 ± 11.7
IL-10 100.0 ± 7.7 118.4 ± 8.1
IL-15 100.0 ± 6.1 103.4 ± 6.0
FAS 100.0 ± 12.6 114.9 ± 14.4
UCP2 100.0 ± 4.4 110.3 ± 6.1
Valuesareexpressedas%ofbaselineaveragelevel(mean+SEM). ∗P = 0.05
and ∗∗P<0.01 compared to baseline, paired t-test. TNF: tumor necrosis
factor; IL: interleukin; MCP: monocyte chemoattractant protein; FAS: fatty
acid synthase; UCP: uncoupling protein. n = 55.
Table 5: Vitamin D parameters before and after a 12-week inter-
vention of low-dairy (LD) or adequate dairy (AD) diets.
Adequate dairy
Run-in Week 12
25(OH)D, nmol/L 30.8 ± 12.4a 35.1 ± 12.8b
1,25(OH)2D, pmol/L 120.9 ± 21.9 107.4 ± 32.1
Low dairy
25(OH)D, nmol/L 38.7 ± 16.7b 39.6 ± 18.1bc
1,25(OH)2D, pmol/L 120.5 ± 24.6 116.3 ± 31.5
Values are mean + standard deviation.
Diﬀerent superscripts denote signiﬁcant diﬀerence between treatment
groups (P = 0.02) and over time (P = 0.0009).
during the course of the study, with modest but signiﬁcant
increases in CD11d and IL-6 mRNA levels observed.
A signiﬁcant treatment eﬀect (P = 0.02) was observed
for serum vitamin D concentrations (Table 5). The AD
group initially had signiﬁcantly lower serum 25(OH)D
values compared to the LD group at the run-in period
(Table 5), but there was a signiﬁcant increase (P = 0.0009) in
the percent change in 25(OH)D in the AD group with
approximately a 17% increase by the end of the 12-week
intervention. However, examination of the range of values
(12–78nmol/L) indicates that some participants continued
to have insuﬃcient levels of 25(OH)D. At run-in, 86% of
all subjects had serum values less than 50nmol/L while at
the 12-week time point, 79% had values <50nmol/L. As
expected, there was a small, but signiﬁcant relationship
between serum 25(OH)D and parathyroid hormone (r =
0.18; P = 0.036). No signiﬁcant changes were observed in
1,25(OH)2D by treatment group; however, there was a trend
(P = 0.06)towardasigniﬁcantincreaseinthepercentchange
of 1,25(OH)2D in the AD group at the end of the 12-week
intervention; ∼7.5% increase for the AD group compared to
∼1% decline in the LD group.Journal of Obesity 9
Table 6: Energy expenditure and physical activity characteristics in
adult women and men consuming adequate dairy (AD) or low-
dairy (LD) diets for 12 weeks on a caloric-restricted diet.
Adequate dairy
Run-in Week 12
Respiratory exchange
ratio: fasting 0.84 ±0.05 0.84 ±0.05
Respiratory exchange
ratio: postprandial 0.85 ±0.03 0.85 ±0.03
Resting metabolic rate
(RMR), kcal/d 1750 ±272 1685 ±269
Postprandial metabolic
rate (PPMR), kcal 1995a ±306 1894b ±274
Total activity
expenditure, kcal/d 814 ±354 719 ±280
Sedentary activity,
min/d 1049.0 ±102.9 1059.0 ±92.5
Light activity, min/d 200.3 ±53.8 206.7 ±41.8
Moderate activity,
min/d 152.9 ±59.6 148.3 ±56.7
Low dairy
Run-in Week 12
Respiratory exchange
ratio: fasting 0.83 ±0.04 0.84 ±0.05
Respiratory exchange
ratio: postprandial 0.83 ±0.03 0.83 ±0.03
Resting metabolic rate
(RMR), kcal/d 1709.0 ±315.6 1638.0 ±325.3
Postprandial metabolic
rate (PPMR), kcal 1921a ±292 1856b ±240
Total activity
expenditure, kcal/d 716 ±328 654 ±291
Sedentary activity,
min/d 1046.0 ±121.3 1066.0 ±116.1
Light activity, min/d 207.4 ±57.3 207.5 ±8.2
Moderate activity,
min/d 140.1 ±68.1 136.1 ±64.0
Values are mean + SD; diﬀerent superscripts denote signiﬁcant diﬀerence
over time.
No signiﬁcant dairy treatment diﬀerences were observed
intheRERafteranovernightfast.However,theaveragepost-
prandial (PP) RER measured during the 10-h postprandial
protocol was signiﬁcantly higher in the AD group at run-in
and after intervention (P<0.03) (Table 6). After controlling
for fat-free mass, RMR was not diﬀerent over time or bet-
ween treatment groups, whereas PPMR was signiﬁcantly
lower at week 12 for both the AD and LD groups (P<0.001)
and did not diﬀer between groups (Table 6). No signiﬁcant
diﬀerence was observed between treatment groups for total
activity energy expenditure over time, as measured by
total activity counts from the Actical monitors. The energy
expenditure for daily activities represented approximately
42–46% of RMR at baseline for the AD and LD groups,
respectively.Valuesfortotalactivityexpenditureweresimilar
at the end of the study, representing ∼40–43% of RMR.
Table 7: Total activity counts per day in women and men consum-
ing adequate dairy (AD) or low-dairy (LD) diets for 12 weeks on a
caloric-restricted diet.
Adequate dairy
Week 1 Week 4 Week 8 Week 12
207,846.7a±
123,696.7
198,531.6a±
90,535.9
175,796.1b±
99,638.0
180,292.1c±
116,312.3
Low dairy
163,390.3a±
90,640.4
174,650.1a±
104,178.9
159,193.9a±
84,882.5
151,193.1a±
86,144.2
Values are mean ± SD; diﬀerent superscripts denote signiﬁcant diﬀerences
between weeks within treatment groups. No diﬀerences were observed
between groups in total activity counts.
When the activity data were examined based on the total
activity counts, the AD group demonstrated a slight decline
in activity from the run-in period to that observed at 8 and
12 weeks of intervention (Table 7). Although not statistically
diﬀerent from the total activity count for the LD group, the
decline in activity for the AD group was approximately
13–15%. Using all subjects, there was a signiﬁcant positive
association between the change in body weight and total
energy expenditure from daily physical activity (r = 0.33;
P = 0.0095). Similar associations were observed between the
changeinbodyweightandtheamountoftime(min/d)spent
in light and moderate activity (R2 = 0.145 and R2 = 0.147,
resp.). Approximately 14% of the variance in the change
in body weight could be explained by the amount of time
spent in light or moderate activity. Conversely, a signiﬁcant
negative association was observed between change in body
weight and amount of time spent in sedentary activity (r =
−0.38; P = 0.0025). Similar relationships were observed
between the change in body fat and time spent in light or
moderate physical activity.
Fasting serum lipids showed no change for those con-
suming the AD diet; total cholesterol, LDL, and HDL choles-
terol were not higher in the AD group compared to the
LD group following intervention (Table 8). Similarly fasting
glucose, insulin, or HOMA did not change between groups;
however, fasting insulin changed over time with a decrease of
about12%associatedwithweightloss.Fasting levelsofother
metabolism-related hormones were also examined. No sig-
niﬁcant diﬀerence was observed between treatment groups
or over time for leptin or adiponectin. Circulating levels for
the proinﬂammatory cytokines Il-1β, Il-6, Il-8, and TNF-α,
and hs-CRP did not change with treatment but did decline
signiﬁcantly over time associated with weight loss (Table 9).
5. Discussion
Wedemonstratedthattheinclusionof3-4servings/dofdairy
foods in a moderate energy-restricted diet for overweight
and obese individuals, who were low-dairy consumers at
initiation of the study, did not result in signiﬁcantly greater
amounts of central fat and weight loss compared to an
energy-restricted diet with ≤1 serving of dairy/d. Addition-
ally, we did not observe greater IAAT loss for the subjects
consuming the AD diet, nor a greater reduction in adipose10 Journal of Obesity
Table 8: Serum lipids, glucose, and insulin parameters in women and men consuming adequate dairy (AD) or low-dairy (LD) diets for 12
weeks.
Parameter Adequate dairy Low dairy
Run-in Week 12 Run-in Week 12
Cholesterol, mmol/L 4.09 + 0.74 4.08 + 0.81 4.16 + 0.69 4.12 + 0.81
(mg/dL) (158.1 + 28.6) (157.8 + 31.1) (160.5 + 26.9) (159.2 + 31.3)
LDL, mmol/L 2.69 + 0.61 2.97 + 0.61 2.74 + 0.52 2.74 + 0.68
(mg/dL) (103.7 + 23.5) (102.9 + 23.7) (105.7 + 20.0) (105.8 + 26.4)
HDL, mmol/L 0.96 + 0.29 0.93 + 0.30 0.95 + 0.31 0.92 + 0.28
(mg/dL) (37.0 + 12.2) (36.1 + 11.6) (36.5 + 11.9) (35.6 + 10.9)
Glucose, mmol/L 4.6 + 0.5 4.8 + 0.5 4.6 + 0.5 4.7 + 0.4
(mg/dL) (83.6 + 9.1) (86.3 + 8.8) (82.5 + 8.2) (84.9 + 7.1)
Insulin, pmol/L 271.2 + 210.7 229.7 + 151.1 225.7 + 112.7 205.7 + 101.4
HOMA 3.1 + 2.4 2.7 + 1.8 2.6 + 1.4 2.4 + 1.2
Values are mean + SD.
tissue gene expression of inﬂammatory markers or in cir-
culating inﬂammatory cytokines. The ﬁndings of the present
study are in agreement with results reported by some inves-
tigators [5, 8–10, 21] but in contrast with other studies that
demonstrated a greater reduction in fat mass with dairy in-
tervention [6, 7, 11, 12, 22, 23]. Researchers in Australia [24]
compared 3 servings of dairy foods per day to 5 servings/d,
within the context of a reduced calorie diet, on changes in
body weight and fat in overweight individuals during a 12-
weekintervention.Theyreportedsigniﬁcantlygreaterweight
and fat loss in the group receiving 5servings of dairy/d.
Kadooka et al. [25] reported a signiﬁcant decreasein abdom-
inal visceral fat in obese adults who received fermented milk
(e.g., yogurt with probiotics), and Faghih et al. [26]c o m -
pared the eﬀect of cow’s milk, fortiﬁed soy milk, and calcium
supplementation on weight and fat loss, reporting a signif-
icant treatment eﬀect with the cow milk group having the
greatest weight loss. Diﬀerences in outcomes across clinical
studies with dairy and calcium interventions might be
explained by the lack of control for individual diﬀerences in
food self-selection during dietary intervention with diﬀerent
amounts of dairy and/or calcium (e.g., changes in intakes of
fats or other calorie sources due to experimental interven-
tions). However, by providing all the food for the present
study and matching subjects on adiposity, our study allowed
for a direct assessment of the eﬀects of increasing dairy
a n dc a l c i u mc o n s u m p t i o no nm e t a b o l i co u t c o m e sw i t h o u t
confounding eﬀects of other dietary changes that may occur
in free-living research volunteers.
Another possibility for our discrepant results compared
to prior studies may be the “dairy eﬀect” requires a longer
period of time to see an impact on weight gain and fat ac-
cumulation over time rather than an eﬀect on weight and fat
loss. Speciﬁc to this point is the research by Gunther et al.
[21] and Eagan et al. [22]. Gunther and colleagues doc-
umented no beneﬁt of dairy products to modulate body
weight or fat mass in young free-living women over a 1-year
intervention. However, a six month followup by Eagan et
al. [22] with the same group of women found a signiﬁcant
eﬀect of dietary calcium to reduce body fat accumulation.
Research by Bush et al. [23] also found that dietary calcium
Table 9: Endocrine hormones and inﬂammatory cytokines in
women and men consuming adequate-dairy (AD) or low-dairy
(LD) diets following a 12 week intervention.
Adequate dairy Low dairy
Run-in Week 12 Run-in Week 12
Leptin,
ng/mL 39.5 + 23.7 29.5 + 24.0 28.7 + 21.0 21.7 + 16.5
Adiponectin,
ug/mL 13.7 ± 7.2 13.8 ± 6.7 14.7 ± 7.6 15.2 ± 7.1
PAI-1, Um/L 19.2 ± 16.3 16.0 ± 11.3 21.5 ± 15.6 19.5 ± 19.1
IL-1β, pg/mL 0.56 + 1.12 0.41 + 0.69 0.48 + 0.47 0.48 + 0.51
IL-6 pg/mL 3.38 + 2.86 3.20 + 2.72 3.97 + 4.97 3.30 + 3.96
IL-8, pg/mL 1.58 + 1.10 1.53 + 0.67 1.51 + 0.85 1.61 + 1.01
TNF-α,
pg/mL 3.15 + 1.65 3.07 + 1.51 3.07 + 1.63 3.19 + 1.46
hs-CRP, mg/L 3.4 + 4.5 2.4 + 2.4 2.5 + 3.3 2.1 + 3.8
Values are mean + SD.
IL: interleukin; TNF: tumor necrosis factor; hsCRP: high-sensitivity C-
reactive protein.
intake was signiﬁcantly associated with less gain in IAAT
over 1yr. in premenopausal women. These studies suggest
that any eﬀect of dairy intake may be cumulative over a
longer period of time, perhaps as part of a satiety/appetite
regulation mechanism. More recently research, reported by
G i l b e r te ta l . ,[ 27] provided more evidence of an appetite-
suppression eﬀect of dairy foods. Speciﬁcally, in a 6 mo. milk
supplementation single-blind placebo-controlled weight loss
trial, there was a signiﬁcant treatment by time interaction
that resulted in a smaller increase in desire to eat and hunger,
suggesting that incorporation of milk into a weight loss diet
modulatestheorexigeniceﬀectofweightloss.Thecontrolled
feeding design of the present study, allowing for the control
of all food intake, prevented us from being able to observe a
similar inﬂuence of dairy foods on appetite and hunger and
a voluntary reduction of food and energy intake. Regardless,
an important point to make is that while increasing dairy
consumption did not increase fat or weight loss, inclusion
of dairy foods in a weight loss paradigm did not compromise
weight loss.Journal of Obesity 11
Furthermore,wedidnotseeanadverseincreaseinserum
lipids as a result of the AD diet which is in contrast to the
ﬁndings of Wennersberg et al. [28]. The diﬀerence between
our results and those of Wennersberg et al. can be explained
by the diﬀerence in the dairy foods incorporated into our
menu. We used 1 or 2% fat milk (depending on caloric
needs), low-fat yogurt, and full-fat cheese with saturated,
mono- and polyunsaturated fats balanced between the LD
and AD menus. Wennersberg et al. used a higher fat diet and
includedmoresaturatedfats,forexample,cream12–40%fat,
cheese 15–30% fat, and butter or butter spreads 40–80% fat.
T h e r eh a v eb e e nm i x e dr e p o r t so nt h ee ﬀect of calcium
intake to promote fat substrate utilization [4, 5, 29, 30],
which could be a potential mechanism by which increased
calcium or dairy intake impacts weight and fat loss. Melan-
son et al. [31] examined 24-h energy expenditure, using a
room calorimeter, in a group of healthy, young adult, non-
obese men and women and reported that an acute intake
of calcium was positively correlated with fat oxidation over
24hrs, during sleep, and during light physical activity. Also,
acute calcium intake was inversely related to 24-h RER. Con-
versely, habitual calcium intake was not associated with in-
creased fat oxidation. In contrast, Jacobsen and colleagues
[11] reported that in young normal-weight adults under
isocaloric conditions, short-term calcium intake, as high as
1800mg/d, had no eﬀect on total energy expenditure or fat
oxidation, but fecal fat excretion increased about 2.5-fold.
Teegarden and coworkers [12] examined energy expenditure
and fat oxidation in 24 young adult overweight women
and found (after controlling for fat-free mass) that those
taking 900mg/d as calcium supplements had a signiﬁcantly
higher (P = 0.02) rate of fat oxidation after a test meal
challenge (1.5g/hr) compared to the control group or those
consuming 900mg/Ca via dairy foods. Cumming et al. [29]
reported signiﬁcantly higher rates of fat oxidation in a group
of middle-aged overweight and obese men and women fol-
lowing a high-calcium breakfast meal, either dairy or sup-
plements, compared to the low-calcium breakfast. Although
our subject characteristics were similar to those of Teegarden
et al. and Cumming et al., we did not observe signiﬁcant
diﬀerences in the fasting RER, a measure of substrate uti-
lization. However, we did observe that our AD group had a
signiﬁcantly higher postprandial RER compared to the LD
group, but this diﬀerence was observed prior to initiation
of the intervention diets, suggesting that there were inherent
diﬀerences in substrate utilization between the groups.
The work of Zemel et al. [3], Shi et al. [30], and Sun and
Zemel [32] in animal models and in vitro studies suggest that
calciumandordairyfoodmaybeasigniﬁcantcontributorto
greaterweightandfatloss.SunandZemel[32]demonstrated
that high-calcium diets shift energy partitionin, thereby
reducing weight gain during refeeding in obese mice. Based
on the work of these investigators, vitamin D status (cal-
citriol, speciﬁcally) and its relationship to metabolic status
are instrumental to the underlying hypothesis that the
inclusion of dairy foods in a moderate energy-restricted
diet will result in greater weight and fat loss. In our study,
the overall values for serum vitamin D remained relatively
stable in both groups (LD: 38.7 and 39.6nmol/L; AD: 30.8
and 35.1nmol/L), and serum calcitriol concentrations were
not diﬀerent between the LD and AD treatments (Table 5).
Furthermore, the stability of the vitamin D levels explains
the lack of a signiﬁcant change in serum PTH. Therefore, we
cannot discount the possibility that under our experimental
conditions, the absence of dairy treatment eﬀects on fat loss
and inﬂammatory parameters may be explained in part by
the lack of treatment-related changes in blood calcitriol
levels.AlthoughtheADdietprovidedgreaterdietaryvitamin
D intake, there was not a suﬃcient increase in circulating
vitamin D to have a suppression eﬀect. Furthermore, the ob-
served increase in vitamin D was statistically signiﬁcant; the
absolute values was substantially lower than the recom-
mended level. Our ﬁndings are in contrast to those reported
by Cann et al. [33] from Women’s Health Initiative (WHI)
whichdemonstratedasmall,butstatisticallysigniﬁcanteﬀect
of calcium and vitamin D to reduce weight gain over three
years. Postmenopausal women with less than 1200mg/d Ca
intake at baseline and randomized to supplements were 11%
less likely to experience small (1–3kg) and modest (>3kg)
gains in weight. The exceptionally large sample size and the
multiple years of followup for this study enabled the investi-
gators to detect small changes in weight gain. Unfortunately,
Cann and colleagues do not report serum levels for either
25-OH vitamin D or 1,25(OH)2 vitamin D at baseline or for
3-year followup that we might be able to compare results
based on actual serum levels of vitamin D. Additionally,
the WHI research volunteers were postmenopausal women
with a diﬀerent endocrine proﬁle than our women who
were premenopausal. A postmenopausal endocrine proﬁle
maybemoreresponsive totheinﬂuenceofhigh-calciumand
vitamin D intakes than those in premenopausal women and
adult men that were research volunteers in the present study.
The short duration and small sample size of the present
study did not allow us to detect changes in body weight or
body fat as small as 1kg as observed in the WHI data. Addi-
tionally, a statistically signiﬁcant ﬁnding for an outcome var-
iable of weight gain over time is not the same as testing the
outcome variable of weight loss and, therefore, cannot be
directly compared.
Adipose tissue is an active endocrine organ that releases a
number of metabolism-related hormones and cytokines into
the circulation, and obesity is often marked by sub-clinical
inﬂammation and WAT macrophage inﬁltration. However,
research ﬁndings in this area [34–36] have reported conﬂict-
ing results. We observed no changes in gluteal subcutaneous
WAT inﬂammatory markers in our overweight and obese
adultsevenwithweightloss.Oursubjectshadlowcirculating
levels of inﬂammatory markers at the start of the study, sug-
gesting there was no underlying inﬂammation at the time
of enrollment, and; therefore, no improvement could be
detected with treatment. Furthermore, the hs-CRP values in
our study subjects at the outset were on average within the
AHA/CDC recommended normal range (1.0–3.1mg/L)
[36]. However, we did see small, but statistically signiﬁcant
improvements in leptin, CRP, and PAI-1 associated with
weight loss.
Weight loss studies that focus on dietary interven-
tions generally instruct the volunteers to maintain current12 Journal of Obesity
physical activity levels; however, supporting data to conﬁrm
compliance with this request are generally lacking. In our
study we demonstrated no change in daily physical activity
level in the LD group over time and a small (∼13–15%)
decline in the AD group. However, due to the large variation
in total activity counts (standard deviations of ∼90,000
and 120,000 counts), there was no signiﬁcant diﬀerence in
activity between groups. Nonetheless, the ∼13–15% reduc-
tion in activity counting in the AD group during the latter
half of the intervention may have resulted in somewhat less
weight loss and fat loss as a result of a lower energy expen-
diture. To more thoroughly examine this possibility, we
correctedenergyexpenditureforbodyweightandthechange
in body weight over the course of the intervention. When
energy expenditure associated with daily physical activity
was corrected for body weight, no diﬀerences were observed
between the treatment groups. We also saw no signiﬁcant
change in lean body mass, and; thus, no change in the resting
metabolic rate. Respiratory exchange ratio also did not
change suggesting no change in substrate utilization between
thegroups.Insummary,thefactthatweobservednochanges
in lean mass, RMR, RER, and physical activity energy
expenditure provide additional support for the concept that
the change in body weight, body fat, and IAAT was due to
caloric restriction and not other factors.
A limitation of our study was the power calculation and
sample size determination. Although our calculations were
based on previous research results, we may have been too
ambitious in our expectation that we would observe more
than a 4kg diﬀerence in weight loss between the groups. In
retrospect, a poststudy power analysis revealed a sample size
o f1 1 2s u b j e c t sp e rg r o u pi no r d e rt od e t e c ta1k gd i ﬀerence
in body weight ±3kg standard deviation with 80 percent
power and an alpha level of 0.05. Our inability to see treat-
ment-related changes in endocrine and inﬂammatory pa-
rameters may also have been due to our strict inclusion
criteria,particularlysincehealthysubjectswithoutmetabolic
abnormalities may have had little room for improvement in
their endocrine or inﬂammatory parameters. Additionally,
the BMI range was limited to overweight and moderately
obese individuals, thereby limiting comorbidities commonly
seen with heavier individuals. Thus, inﬂammatory markers
after weight loss may not similarly reﬂect those markers in
body-weight- and adiposity-matched subjects that have not
lost weight. Whether the inclusion of an adequate number
of dairy servings in weight reduction diets of more obese
individuals with metabolic disturbances improves metabolic
and inﬂammatory parameters deserves further investigation.
In conclusion, the addition of 3-4 servings of dairy foods
in a moderate energy-restricted diet of overweight and obese
adult women and men did not result in greater weight and
fat loss compared to the low-dairy diet. However, no adverse
eﬀects were seen on serum lipids with the inclusion of
3-4 servings of dairy foods, and increasing dairy and calcium
intakes in the course of a calorie-restricted diet did not
compromisefatorweightloss.Thus,giventheimportanceof
calcium and vitamin D to bone health, for weight loss diets
that meet the US Dietary Guidelines for dairy foods, calcium
and vitamin D are recommended. Whether increased dairy
intakeduringweightlossresultsingreaterweightandfatloss
for individuals with metabolic syndrome deserves further
investigation, but attention to study duration, controlled or
free-living environment, and suﬃcient sample size will be
critical for the detection of signiﬁcant changes due to treat-
ment. Consideration should also be given to assessment of
appetite, hunger, and satiety with postintervention followup
on weight regain.
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